EcoDrugPlus

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCPOG00000011012
Gene Symbol: SRC
4 Cross references
261 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSCPOG00000009907
Gene Symbol: TEK
2 Cross references
166 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSCPOG00000009181
Gene Symbol: UGCG
4 Cross references
212 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSCPOG00000003116
Gene Symbol: WEE1
2 Cross references
227 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSCPOG00000015578
Gene Symbol: YES1
2 Cross references
260 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSCPOG00000001746
Gene Symbol: ACHE
2 Cross references
234 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSCPOG00000001660
Gene Symbol: ACVRL1
2 Cross references
358 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSCPOG00000009106
Gene Symbol: ACVR2B
2 Cross references
259 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSCPOG00000032582
Gene Symbol: ADORA1
2 Cross references
275 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSCPOG00000006104
Gene Symbol: ADORA2A
4 Cross references
264 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSCPOG00000038921
Gene Symbol: ADORA2B
4 Cross references
201 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSCPOG00000032151
Gene Symbol: ADORA3
2 Cross references
273 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).